Donor-derived cell-free DNA-based liquid biopsies to determine future kidney transplant rejection
10.23876/j.krcp.23.286
- Author:
Weiwei WANG
;
Cuello Garcia HAIDER
;
Yinfeng WANG
;
Zhoufan ZHANG
;
Yuelin LIU
;
Fengcheng XUE
;
Haitao LIU
;
Tingya JIANG
;
Jingyi CAO
;
Yang ZHOU
- Publication Type:Review Article
- From:Kidney Research and Clinical Practice
2025;44(5):705-725
- CountryRepublic of Korea
- Language:English
-
Abstract:
Donor-derived cell-free DNA (dd-cfDNA) based liquid kidney biopsies have the potential to detect the chances of kidney transplant rejection. Several studies have found that dd-cfDNA can be used to determine the risk of kidney transplant rejection and may correlate with antibody-mediated rejection (ABMR), T cell-mediated rejection (TCMR), and estimated glomerular filtration rate (eGFR). A high concentration of dd-cfDNA in the body fluids may indicate possible transplant rejection since dd-cfDNA is released as a result of apoptotic and necrotic processes initiated by the recipient’s immune system. dd-cfDNA assays have advantages over conventional biopsies since they are noninvasive, and therefore, have the potential to provide a safe and reliable biomarker. Different dd-cfDNA levels have been reported above a number of cutoff thresholds: ABMR at 2.45% and TCMR at 1.3%, compared with 0.44% in healthy patients; and eGFR at 2.5%, a decrease of 25% compared with healthy patients. These results indicate the levels of dd-cfDNA that may be used to signal possible kidney rejection. dd-cfDNA assay is a rapid technique, making it particularly useful in emergencies, and further research into its use in the study of kidney rejection should prove beneficial.
